UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]
NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company
January 13, 2020 No Comment
NeuroBo Pharmaceuticals, a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH). The new combined company will be called NeuroBo Pharmaceuticals, which will focus on advancing a clinical-stage pipeline targeting neurodegenerative diseases. NeuroBo, […]
Continue reading …
Eisai and Biogen have decided to stop the MISSION AD1 and AD2 phase 3 clinical studies on elenbecestat in early Alzheimer’s disease (AD) owing to safety concerns, as per the latest clinical trial news. The decision has been driven by the findings of a safety review undertaken by the Data Safety Monitoring Board (DSMB), which […]
Continue reading …
Neuropore Therapies has secured orphan drug designation for NPT520-34 from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). The California-based biopharma company said that the orphan drug designation will enable the development of NPT520-34 in the treatment of the debilitating medical condition for which there are not many […]
Continue reading …
AgeneBio, a US-based CNS biopharma company, enrolled the first patient in a phase 3 clinical trial to study the efficacy of AGB101 for the treatment of amnestic Mild Cognitive Impairment caused by Alzheimer’s Disease (MCI due to AD). The late-stage trial, known as HOPE4MCI, will enroll a total of 830 patients, aged between 55 and […]
Continue reading …
As per the latest reports from the experts, an effective drug to treat Alzeihmer’s disease will be available soon and also a vaccine to prevent Alzeihmer’s disease could also be available within a decade. Clinical trails on 12 drugs is being carried out which could be life-changing and the trials will be completed by 2021. […]
Continue reading …
Business News Today
- Apollo to invest $265m in Maryland offshore wind project owner US Wind
- Liberty Steel Group to acquire Hayange and Ascoval steel plants in France
- TEMCO smelter in Tasmania to be acquired by Sanjeev Gupta’s GFG Alliance
- AGC Networks acquires communications technology firm Pyrios
- Manna Pro Products acquires online pet brand Doggie Dailies
- MedCrypt acquires medical device cybersecurity software firm MedISAO
- Improving acquires custom software development firm Object Partners
- High Street Insurance acquires Michigan-based Capital Insurance Group
- US department store chain Stein Mart files for bankruptcy protection
- Mill Creek Residential breaks ground on Modera Washington in Houston
